Skip to content

Trial · Interventional

RecruitingPhase 1Registry data

Assessing the Safety and Tolerability of NMN in DHDDS-CDG

Overview

Status
Recruiting
Phase
Phase 1
Enrollment
8 participants (estimated)
Sponsor
Eva Morava-Kozicz · Other
Design
Allocation not applicable · Open label (no masking)
Countries
1 country

United States

Start
8 May 2026
Primary completion
1 Aug 2027 (estimated)
Completion
1 Aug 2027 (estimated)
First posted
7 May 2026
Last update posted
22 Jun 2026
Conditions
DHDDS-Congenital Disorder of Glycosylation · DHDDS-CDG · Congenital Disorder of Glycosylation

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202620272028
  1. Ph 1

    Assessing the Safety and Tolerability of NMN in DHDDS-CDG

    NCT07572825

    8 May 2026 to est. 1 Aug 2027

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow healthcare providers to make informed decisions about recommending this dietary supplement in this population.

Interventions

  • Nicotinamide Mononucleotide (NMN) NucleosidaseDrug

Arms1

  • Experimental

    nicotinamide mononucleotide (NMN)

    Participants will take 250mg NMN daily.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Incidence of adverse events (AEs)

    Time frame · up to 12 months

    Registry description

    Incidence of AEs will be collected throughout the treatment period and optional long-term safety follow up period.

Secondary outcomes(3)
  1. International Cooperative Ataxia Rating Scale (ICARS) Score

    Time frame · Baseline, 6 months, 12 months

    Registry description

    Change in ICARS score from baseline to end of the treatment period (6 months) and long term follow up (12 months). The minimal score is 0 and the maximum score is 100, with a higher score indicating greater impairment as a result of ataxia.

  2. Composite gait stability score (Cord walking test performance)

    Time frame · Baseline, 6 months, 12 months

    Registry description

    Cord walking performance will be quantified using a standardized video-based computer vision pipeline applied to semi-structured recordings of participants walking along a straight line. Markerless pose estimation algorithms will extract time-resolved body keypoints, from which predefined gait and postural metrics will be derived, including step width variability, step length consistency, lateral deviation from the walking path, and trunk instability (e.g., standard deviation of body lean). Each metric will be summarized per recording and combined into a composite gait stability score using a prespecified algorithm. Change from baseline to 6 and 12 months will be calculated as within-subject differences in these quantitative measures, enabling objective assessment of gait abnormalities over time.

  3. Composite tremor severity score (Archimedes spiral test performance)

    Time frame · Baseline, 6 months, 12 months

    Registry description

    Archimedes spiral test performance will be quantified using standardized digital analysis of recorded spiral drawings. Video or image inputs will be processed to extract the drawn trajectory, and quantitative features of tremor and motor control will be computed, including line deviation from an ideal spiral template, tremor amplitude (spatial variability), frequency of oscillations, and drawing smoothness (e.g., velocity and jerk metrics). These features will be aggregated into a composite tremor severity score using a predefined scoring framework. Change from baseline to 6 and 12 months will be assessed as within-subject differences in these quantitative metrics, providing an objective measure of hand tremor severity and progression.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 4 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Subject is ≥ 4 years old * Subject has biologically and genetically proven heterozygous DHDDS-CDG. * Subject/legally authorized representative (LAR) is able to understand and provide written informed consent, and assent (as applicable) to participate in this study. Exclusion Criteria: * Subject has intellectual disability with IQ\<52 (moderate or lower IQ intellectual disability). * In the site Principal Investigator's opinion, subject has a history of intolerance to NMN or other niacin metabolite supplement that precludes the subject from participation in this study. * Subject has any of the following: * Liver failure * ALT level \>5x ULN * AST level \>5x ULN * eGFR \< 30 OR creatinine \>180 mmol/L * Subject is pregnant. * Use of investigational compounds within the previous 6 months or current enrollment in another trial involving investigational compounds. * Concomitant use of the following medications that could interact with orally administered NMN: * Aspirin * Metformin * Statins or other cholesterol-lowering drugs * In the site Principal Investigator's opinion, subject is not able or willing to comply with the trial requirements.

PepBank is a research reference. Talk to a doctor before you use any peptide.